Jennerex, a clinical-stage cancer biotherapeutics company, has appointed Gregory Schafer as senior vice president (SVP) and chief financial officer (CFO). He will be responsible for the company’s finance, accounting, planning, investor relations and treasury functions.
Schafer brings more than 20 years of broad functional and strategic leadership expertise to Jennerex and has raised over US$600m in public and private transactions to fund biotechnology product development and commercialisation activities. Most recently, he served as CFO of Onyx Pharmaceuticals, where he was responsible for finance, accounting, risk management, and strategic and operational planning.
Prior to Onyx, he served as CFO and vice president of finance for Cerus Corporation, where he played a key role in transitioning the company from early-stage development to a commercial enterprise with an approved product. Prior to Cerus, Schafer worked as a management consultant for Deloitte and Touche, and as an engineer specialising in biologics manufacturing. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company. He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.